Literature DB >> 22209390

Reirradiation of paraaortic lymph node metastasis by brachytherapy with hyaluronate injection via paravertebral approach: With DVH comparison to IMRT.

Kazushi Kishi1, Tetsuo Sonomura, Shintaro Shirai, Yasutaka Noda, Morio Sato, Hitoshi Ikushima, Ryoong-Jin Oh.   

Abstract

UNLABELLED: PURPOSE/
INTRODUCTION: To safely irradiate retroperitoneal targets as paraaortic lymph node by separating abdominal at-risk organs from the target during irradiation, we created a percutaneous paravertebral approach of high-dose-rate brachytherapy with hyaluronate gel injection (HGI). We report a case treated with this technique. METHODS AND MATERIALS: We encountered a patient with symptomatic regrowth of paraaortic lymph node metastasis from prostatic cancer. He had previously received 58.4Gy of radiotherapy to the same region 12 months prior. Brachytherapy needles and a HGI needle were deployed via the paravertebral approach under local anesthesia at our outpatient clinic.
RESULTS: A single dose of 22.5Gy (equivalent to 60.94Gy in 2Gy per fraction schedule calculated at α/β=10) was delivered to the target, with preservation of the surrounding small intestine by HGI with D(2cc) (minimum dose to the most irradiated volume of 2mL) of 5.05Gy. Therapeutic ratio was 3.64 times higher for this brachytherapy plan compared with an intensity-modulated radiation therapy plan. At followup at 1 year after brachytherapy, the symptoms had disappeared, tumor size had reduced with no fluorodeoxyglucose accumulation, and prostate-specific antigen level had decreased.
CONCLUSION: We consider that high-dose-rate brachytherapy with the HGI procedure offers effective treatment even in this type of reirradiation situation.
Copyright © 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209390     DOI: 10.1016/j.brachy.2011.12.004

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  7 in total

1.  Novel eradicative high-dose rate brachytherapy for internal mammary lymph node metastasis from breast cancer.

Authors:  Kazushi Kishi; Hirokazu Tanino; Tetsuo Sonomura; Shintaro Shirai; Yasutaka Noda; Morio Sato; Yoshitaka Okamura
Journal:  World J Radiol       Date:  2012-11-28

Review 2.  Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.

Authors:  Ansje S Fortuin; Robert Jan Smeenk; Hanneke J M Meijer; Alfred J Witjes; Jelle O Barentsz
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

3.  Esophageal gel-shifting technique facilitating eradicative boost or reirradiation to upper mediastinal targets of recurrent nerve lymph node without damaging esophagus.

Authors:  Kazushi Kishi; Takeshi Iida; Toshiyasu Ojima; Tetsuo Sonomura; Shintaro Shirai; Motoki Nakai; Morio Sato; Hiroki Yamaue
Journal:  J Radiat Res       Date:  2013-02-21       Impact factor: 2.724

4.  CT-Guided Pelvic Lymph Nodal Brachytherapy.

Authors:  Hiroaki Kunogi; I-Chow Hsu; Nanae Yamaguchi; Soshi Kusunoki; Keiko Nakagawa; Yayoi Sugimori; Kazunari Fujino; Yasuhisa Terao; Daiki Ogishima; Ryoichi Yoshimura; Keisuke Sasai
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

5.  Unresectable bulky chest wall recurrent breast cancer controlled with CT-guided interstitial high-dose-rate brachytherapy and external beam radiotherapy with adjuvant hormonal therapy - case report.

Authors:  Hiroaki Kunogi; I-Chow Hsu; Keisuke Sasai
Journal:  J Contemp Brachytherapy       Date:  2021-08-24

6.  Percutaneous interstitial brachytherapy for adrenal metastasis: technical report.

Authors:  Kazushi Kishi; Shinji Tamura; Yasushi Mabuchi; Tetsuo Sonomura; Yasutaka Noda; Motoki Nakai; Morio Sato; Kazuhiko Ino; Noboru Yamanaka
Journal:  J Radiat Res       Date:  2012-07-17       Impact factor: 2.724

7.  Optimization of re-irradiation using deformable registration: a case study.

Authors:  Raphaël Jumeau; Nicolas Péguret; Cédric Zulliger; Raphaël Moeckli; Jean Bourhis; Esat-Mahmut Ozsahin
Journal:  BJR Case Rep       Date:  2016-05-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.